• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Ginkgo Bioworks Holdings Inc.

    5/15/26 5:48:36 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DNA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    Ginkgo Bioworks Holdings, Inc.

    (Name of Issuer)


    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    37611X209

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    37611X209


    1Names of Reporting Persons

    VIKING GLOBAL INVESTORS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,577,128.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,577,128.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,577,128.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.1 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    37611X209


    1Names of Reporting Persons

    Viking Global Opportunities Parent GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,577,128.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,577,128.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,577,128.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    37611X209


    1Names of Reporting Persons

    Viking Global Opportunities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,577,128.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,577,128.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,577,128.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    37611X209


    1Names of Reporting Persons

    Viking Global Opportunities Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,577,128.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,577,128.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,577,128.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.1 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    37611X209


    1Names of Reporting Persons

    Viking Global Opportunities Illiquid Investments Sub-Master LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,577,128.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,577,128.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,577,128.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.1 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    37611X209


    1Names of Reporting Persons

    HALVORSEN OLE ANDREAS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NORWAY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,577,128.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,577,128.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,577,128.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.1 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    37611X209


    1Names of Reporting Persons

    Shabet Rose Sharon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,577,128.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,577,128.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,577,128.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.1 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Ginkgo Bioworks Holdings, Inc.
    (b)Address of issuer's principal executive offices:

    27 Drydock Avenue, 8th Floor, Boston, MA 02210
    Item 2. 
    (a)Name of person filing:

    Viking Global Investors LP ("VGI"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("VGOP"), O. Andreas Halvorsen and Rose S. Shabet (collectively, the "Reporting Persons") Effective March 31, 2026, David C. Ott ("Mr. Ott") retired from his roles as Advisory Director of VGI and Executive Committee Member of each of Viking Global Partners LLC (the general partner of VGI) and Opportunities Parent. Accordingly, this Amendment No. 4 is being filed to remove Mr. Ott as a Reporting Person from this Schedule 13G, as Mr. Ott is no longer a beneficial owner of any of the shares of Class A Common Stock reported herein.
    (b)Address or principal business office or, if none, residence:

    The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
    (c)Citizenship:

    VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP and Opportunities Portfolio GP are Delaware limited liability companies; VGOP is a Cayman Islands exempted limited partnership; O. Andreas Halvorsen is a citizen of Norway; and Rose S. Shabet is a citizen of the United States.
    (d)Title of class of securities:

    Class A Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    37611X209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    VGI: 3,577,128 VGI provides managerial services to VGOP. VGI has the authority to dispose of and vote the shares of Class A Common Stock directly held by VGOP. VGI does not directly own any shares of Class A Common Stock. Based on Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Act"), VGI may be deemed to beneficially own the shares of Class A Common Stock directly held by VGOP. VGI beneficially owns 3,577,128 shares of Class A Common Stock consisting of (i) 2,900,025 shares of Class A Common Stock directly and beneficially owned by VGOP and (ii) 677,103 shares of Class A Common Stock directly and beneficially owned by VGOP that remain subject to forfeiture to the extent certain price targets are not satisfied. Opportunities Parent: 3,577,128 Opportunities Parent is the sole member of Opportunities GP, which has the authority to dispose of and vote the shares of Class A Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Class A Common Stock directly held by VGOP. Opportunities Parent does not directly own any shares of Class A Common Stock. Based on Rule 13d-3 under the Act, Opportunities Parent may be deemed to beneficially own the shares of Class A Common Stock directly held by VGOP. Opportunities Parent beneficially owns 3,577,128 shares of Class A Common Stock consisting of (i) 2,900,025 shares of Class A Common Stock directly and beneficially owned by VGOP and (ii) 677,103 shares of Class A Common Stock directly and beneficially owned by VGOP that remain subject to forfeiture to the extent certain price targets are not satisfied. Opportunities GP: 3,577,128 Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the shares of Class A Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Class A Common Stock directly held by VGOP. Opportunities GP does not directly own any shares of Class A Common Stock. Based on Rule 13d-3 under the Act, Opportunities GP may be deemed to beneficially own the shares of Class A Common Stock directly held by VGOP. Opportunities GP beneficially owns 3,577,128 shares of Class A Common Stock consisting of (i) 2,900,025 shares of Class A Common Stock directly and beneficially owned by VGOP and (ii) 677,103 shares of Class A Common Stock directly and beneficially owned by VGOP that remain subject to forfeiture to the extent certain price targets are not satisfied. Opportunities Portfolio GP: 3,577,128 Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the shares of Class A Common Stock directly owned by VGOP. Opportunities Portfolio GP does not directly own any shares of Class A Common Stock. Based on Rule 13d-3 under the Act, Opportunities Portfolio GP may be deemed to beneficially own the shares of Class A Common Stock directly held by VGOP. Opportunities Portfolio GP beneficially owns 3,577,128 shares of Class A Common Stock consisting of (i) 2,900,025 shares of Class A Common Stock directly and beneficially owned by VGOP and (ii) 677,103 shares of Class A Common Stock directly and beneficially owned by VGOP that remain subject to forfeiture to the extent certain price targets are not satisfied. VGOP: 3,577,128 VGOP has the authority to dispose of and vote the shares of Class A Common Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP. VGOP directly and beneficially owns 3,577,128 shares of Class A Common Stock consisting of (i) 2,900,025 shares of Class A Common Stock directly and beneficially owned by VGOP and (ii) 677,103 shares of Class A Common Stock directly and beneficially owned by VGOP that remain subject to forfeiture to the extent certain price targets are not satisfied. O. Andreas Halvorsen and Rose S. Shabet: 3,577,128 Mr. Halvorsen and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the shares of Class A Common Stock beneficially owned by VGI and Opportunities Parent. Neither Mr. Halvorsen nor Ms. Shabet directly owns any shares of Class A Common Stock. Based on Rule 13d-3 under the Act, each may be deemed to beneficially own the shares of Class A Common Stock directly held by VGOP. Mr. Halvorsen and Ms. Shabet each beneficially own 3,577,128 shares of Class A Common Stock consisting of (i) 2,900,025 shares of Class A Common Stock directly and beneficially owned by VGOP and (ii) 677,103 shares of Class A Common Stock directly and beneficially owned by VGOP that remain subject to forfeiture to the extent certain price targets are not satisfied.
    (b)Percent of class:

    The percentages set forth herein are based on 50,254,065 shares of Class A Common Stock outstanding as of March 31, 2026, as reported in the Issuer's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "Commission") on May 7, 2026. VGI: 7.1% Opportunities Parent: 7.1% Opportunities GP: 7.1% Opportunities Portfolio GP: 7.1% VGOP: 7.1% O. Andreas Halvorsen and Rose S. Shabet: 7.1%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 O. Andreas Halvorsen and Rose S. Shabet: 0

     (ii) Shared power to vote or to direct the vote:

    VGI: 3,577,128 Opportunities Parent: 3,577,128 Opportunities GP: 3,577,128 Opportunities Portfolio GP: 3,577,128 VGOP: 3,577,128 O. Andreas Halvorsen and Rose S. Shabet: 3,577,128

     (iii) Sole power to dispose or to direct the disposition of:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 O. Andreas Halvorsen and Rose S. Shabet: 0

     (iv) Shared power to dispose or to direct the disposition of:

    VGI: 3,577,128 Opportunities Parent: 3,577,128 Opportunities GP: 3,577,128 Opportunities Portfolio GP: 3,577,128 VGOP: 3,577,128 O. Andreas Halvorsen and Rose S. Shabet: 3,577,128

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The response to Item 4 is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    VIKING GLOBAL INVESTORS LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)
    Date:05/15/2026
     
    Viking Global Opportunities Parent GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)
    Date:05/15/2026
     
    Viking Global Opportunities GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)
    Date:05/15/2026
     
    Viking Global Opportunities Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)
    Date:05/15/2026
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)
    Date:05/15/2026
     
    HALVORSEN OLE ANDREAS
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
    Date:05/15/2026
     
    Shabet Rose Sharon
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (2)
    Date:05/15/2026

    Comments accompanying signature:  (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).
    Exhibit Information

    EXHIBIT A - JOINT FILING AGREEMENT

    Get the next $DNA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNA

    DatePrice TargetRatingAnalyst
    5/15/2024Neutral → Sell
    BTIG Research
    5/10/2024Mkt Perform → Underperform
    William Blair
    11/14/2023$3.50 → $2.50Outperform → Mkt Perform
    Raymond James
    11/9/2023Buy → Neutral
    BTIG Research
    6/2/2023$3.00 → $1.25Neutral → Sell
    Goldman
    5/11/2023Outperform → Mkt Perform
    William Blair
    11/29/2022$6.00Buy
    Berenberg
    10/4/2022$5.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ginkgo Bioworks downgraded by BTIG Research

    BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell

    5/15/24 7:33:13 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks downgraded by William Blair

    William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform

    5/10/24 7:33:29 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks downgraded by Raymond James with a new price target

    Raymond James downgraded Ginkgo Bioworks from Outperform to Mkt Perform and set a new price target of $2.50 from $3.50 previously

    11/14/23 9:04:22 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Coen Steven P. converted options into 743 shares and sold $2,559 worth of shares (307 units at $8.33), increasing direct ownership by 0.87% to 50,704 units (SEC Form 4) (tax liability)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/26/26 5:04:10 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Coen Steven P.

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    4/20/26 5:02:42 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Coen Steven P.

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    4/14/26 5:00:56 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SCHEDULE 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    5/15/26 5:48:36 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.

    10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    5/7/26 4:13:56 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    5/7/26 4:09:31 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

    New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identificationBOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™, a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific and Inductive Bio. ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection

    5/26/26 12:33:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The $59B Quiet Shift Reshaping How Patients Access Care

    Issued on behalf of VentriPoint Diagnostics Ltd.Equity-Insider.com News CommentaryVANCOUVER, BC, May 12, 2026 /CNW/ -- Point-of-care diagnostics just crossed $58.76 billion globally in 2026, growing at nearly 10% annually as testing that used to require a hospital lab now fits on a clinic counter or a patient's nightstand[1]. That capital rotation is real: digital health startups pulled in $4 billion in Q1 alone, the strongest first quarter since the pandemic peak, with average deal sizes at levels not seen since late 2021[2]. Investors are not chasing drug discovery this cycle; they are backing companies that can deliver clinical-grade results through faster, lighter, cheaper channels, and

    5/12/26 10:30:00 AM ET
    $DNA
    $HIMS
    $MNKD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Nursing Services
    Biotechnology: Pharmaceutical Preparations

    Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

    Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity businessBOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com. First Quarter 2026 Financial ResultsAs previously announced, Ginkgo completed the divestiture

    5/7/26 4:05:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sankar Shyam bought $514,750 worth of shares (625,000 units at $0.82), increasing direct ownership by 36% to 2,356,874 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/16/24 5:08:50 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sloan Harry bought $271,815 worth of shares (297,619 units at $0.91), increasing direct ownership by 71% to 718,540 units (SEC Form 4)

    4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

    5/14/24 5:16:23 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Financials

    Live finance-specific insights

    View All

    Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

    Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity businessBOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com. First Quarter 2026 Financial ResultsAs previously announced, Ginkgo completed the divestiture

    5/7/26 4:05:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation

    Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026BOSTON, April 30, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2026, on Thursday, May 7, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.To ask a question ahead of the presen

    4/30/26 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business

    Ginkgo provides an update on its fourth quarter financial resultsBOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Fourth Quarter 2025 Financial ResultsFourth quarter 2025 Total revenue of $33 million compared to $44 million in the comparable prior year pe

    2/26/26 4:26:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Leadership Updates

    Live Leadership Updates

    View All

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy road

    11/4/25 9:00:00 AM ET
    $ASTR
    $BACQ
    $DNA
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Ginkgo Automation Appoints Brian O'Sullivan as Head of Commercial to Accelerate External Growth

    Seasoned life‑science executive to spearhead global go‑to‑market strategy as Ginkgo Automation scales external sales across biopharma, techbio, and new science‑driven markets while continuing to support internal programs. BOSTON, Aug. 12, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the appointment of Brian O'Sullivan as Head of Commercial for Ginkgo Automation. Brian joins Ginkgo Automation from HighRes Biosolutions, where he led their commercial efforts. In his new role, Brian wi

    8/12/25 8:01:00 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $DNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/14/24 4:31:49 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/12/24 3:58:52 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/4/24 11:56:06 AM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care